美國居民不適用 XM 服務。

N
N

Novartis

財經新聞

Reuters - 2天前

Big Pharma bets on AI to speed up clinical trials

INSIGHT-Big Pharma bets on AI to speed up clinical trials Repeats for additional subscribers By Natalie Grover and Martin Coulter LONDON, Sept 22 (Reuters) - Major drugmakers are using artificial intelligence to find patients for clinical trials quickly, or to reduce the number of people needed to test medicines, both accelerating drug development and potentially saving millions of dollars.
A
B
N
R
Reuters - 3天前

Intel antitrust lawyer joins law firm Arnold & Porter in Washington

Intel antitrust lawyer joins law firm Arnold & Porter in Washington By David Thomas Sept 21 (Reuters) - U.S. law firm Arnold & Porter Kaye Scholer said Thursday it has hired the leader of U.S. chipmaker Intel's INTC.O global M&A regulatory practice for its own antitrust practice. David Emanuelson has joined Arnold & Porter's Washington, D.C., office as a partner, the firm said.
I
N
Reuters - 4天前

China's BeiGene falls on terminating cancer drug deal with Novartis

BUZZ-China's BeiGene falls on terminating cancer drug deal with Novartis ** Hong Kong shares of Chinese oncology medicines developer BeiGene Ltd 6160.HK fall as much as 6% to HK$119.40, their lowest since Sept 11 ** Stock on course to snap three straight sessions of gain and for biggest one-day pct decline since Aug 7, if losses hold ** Shanghai-li
N
Reuters - 5天前

Novartis AG Novartis And Beigene Have Mutually Agreed To Terminate The Collaboration And License Agreement For Tislelizumab

BRIEF-Novartis AG Novartis And Beigene Have Mutually Agreed To Terminate The Collaboration And License Agreement For Tislelizumab Sept 19 (Reuters) - Beigene Ltd 6160.HK : NOVARTIS AG: NOVARTIS AND BEIGENE, LTD. HAVE MUTUALLY AGREED TO TERMINATE THE COLLABORATION AND LICENSE AGREEMENT FOR TISLELIZUMAB NOVARTIS AG: WITH TERMINATION, BEIGENE WILL RE-
N
Reuters - 5天前

BeiGene to go solo with cancer drug after Novartis deal termination

UPDATE 3-BeiGene to go solo with cancer drug after Novartis deal termination Adds Novartis statement in paragraphs 6 and 7, BeiGene comments in paragraph 9, analyst's comment in paragraph 10 By Sriparna Roy Sept 19 (Reuters) - BeiGene 6160.HK and Swiss drugmaker Novartis NOVN.S have terminated a 2021 deal to jointly develop the Hong Kong-listed company's cancer drug, the companies said on Tuesday, marking the second such discontinuation in just over two months.
N
Reuters - 5天前

BeiGene regains rights for cancer drug after Novartis deal termination

BeiGene regains rights for cancer drug after Novartis deal termination Sept 19 (Reuters) - BeiGene 6160.HK said on Tuesday it would regain rights to develop and manufacture its cancer drug after a deal termination with Novartis NOVN.S . Reporting by Sriparna Roy in Bengaluru; Editing by Shilpi Majumdar
N
Reuters - 5天前

Beigene Announces Termination Of License Agreement With Novartis

BRIEF-Beigene Announces Termination Of License Agreement With Novartis Sept 19 (Reuters) - Beigene Ltd 6160.HK : BEIGENE SWITZERLAND GRANTED NOVARTIS RIGHT TO DEVELOP, MANUFACTURE AND COMMERCIALIZE TISLELIZUMAB BEIGENE SWITZERLAND AND NOVARTIS ENTERED INTO A MUTUAL TERMINATION AND RELEASE AGREEMENT AGREEMENT TO MUTUALLY TERMINATE LICENSE AGREEMENT
N
Reuters - 6天前

Sandoz Receives Positive CHMP Opinion For Breast And Gastric Cancer Biosimilar Trastuzumab

BRIEF-Sandoz Receives Positive CHMP Opinion For Breast And Gastric Cancer Biosimilar Trastuzumab Sept 18 (Reuters) - NOVARTIS AG NOVN.S : SANDOZ RECEIVES POSITIVE CHMP OPINION FOR BREAST AND GASTRIC CANCER BIOSIMILAR TRASTUZUMAB POSITIVE CHMP OPINION BASED ON COMPREHENSIVE PACKAGE OF ANALYTICAL, PRE-CLINICAL AND CLINICAL DATA BREAST AND GASTRIC CAN
N
Reuters - 1週前

Novartis shareholders vote in favour of Sandoz spin-off

UPDATE 1-Novartis shareholders vote in favour of Sandoz spin-off Adds background on Sandoz CEO interview from 2nd paragraph By Ludwig Burger FRANKFURT, Sept 15 (Reuters) - Novartis NOVN.S shareholders on Friday voted in favour of spinning off the Swiss company's generic-drugs business Sandoz, with investors holding 99.7% of the represented capital supporting the complete separation .
N
P
Reuters - 1週前

Novartis Shareholders Approve The Proposed 100% Spin-Off Of Sandoz

BRIEF-Novartis Shareholders Approve The Proposed 100% Spin-Off Of Sandoz Sept 15 (Reuters) - Novartis Ag NOVN.S : NOVARTIS SHAREHOLDERS APPROVE THE PROPOSED 100% SPIN-OFF OF SANDOZ SHAREHOLDERS ALSO APPROVE A REDUCTION OF SHARE CAPITAL IN CONNECTION WITH SPIN-OFF NOVARTIS SHAREHOLDERS AND NOVARTIS ADR HOLDERS WILL RECEIVE ONE SANDOZ SHARE FOR EVERY
N
Reuters - 1週前

Novartis shareholders vote in favour of Sandoz spin-off

Novartis shareholders vote in favour of Sandoz spin-off FRANKFURT, Sept 15 (Reuters) - Novartis NOVN.S shareholders on Friday voted in favour of spinning off the Swiss company's generic-drugs business Sandoz, with investors holding 99.7% of the represented capital supporting the proposal. Reporting by Ludwig Burger Editing by Miranda Murray
N
Reuters - 1週前

AstraZeneca succession sickness demands urgent fix

BREAKINGVIEWS-AstraZeneca succession sickness demands urgent fix The author is a Reuters Breakingviews columnist. The opinions expressed are her own. By Aimee Donnellan LONDON, Sept 15 (Reuters Breakingviews) - Can a CEO be worth $9 billion? That’s the question posed by the 4% fall in AstraZeneca’s AZN.L shares following an article stating boss Pascal Soriot may soon resign.
A
D
G
N
P
S
Reuters - 1週前

Sandoz dials up product launch plans ahead of market debut

Sandoz dials up product launch plans ahead of market debut By Ludwig Burger and Paul Arnold FRANKFURT, Sept 15 (Reuters) - Sandoz plans to launch at least five additional biologic drugs, its CEO Richard Saynor said, as the generics drugs business of Switzerland's Novartis NOVN.S works to enhance its investor appeal ahead of its market debut next month.
A
B
B
D
F
N
P
R
T
Reuters - 1週前

Sandoz to initially join Swiss mid-cap index after listing - SIX exchange

Sandoz to initially join Swiss mid-cap index after listing - SIX exchange ZURICH, Sept 14 (Reuters) - Generic drugs maker Sandoz, soon to be spun off from Novartis, will not become part of Swiss Exchange SIX's main SMI .SSMI stock index right away, the exchange said on Thursday. Based on the analysis of current market estimates, Sandoz will be included in the mid-cap SMIM .SMIM instead, a spokesperson for the exchange said in response to a Reuters query.
N
S
Reuters - 2週前

How to play a 25 bps hike from the ECB

LIVE MARKETS-How to play a 25 bps hike from the ECB STOXX Europe 600 down 0.1% Airbus sags after Pratt & Whitney engine warning Smurfit Kappa drops after WestRock takeover FTSE 100 gains after UK employment, wage data Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at markets.research@thomsonreuters.com HOW TO PLAY A 25 BPS HIKE FROM THE ECB (1015 GMT) The big event of the week in Europe is the European Central Bank (
A
A
E
N
S
A
S
E
F
U
W
G
Reuters - 2週前

Pharma overtakes tech as most popular in Europe

LIVE MARKETS-Pharma overtakes tech as most popular in Europe STOXX Europe 600 up 0.1% Airbus sags after Pratt & Whitney engine warning Smurfit Kappa drops after WestRock takeover FTSE 100 gains after UK employment, wage data Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at markets.research@thomsonreuters.com PHARMA OVERTAKES TECH AS MOST POPULAR IN EUROPE (1019 GMT) The surge of drugmaker Novo Nordisk NOVOb.CO as mo
A
A
N
S
A
S
E
F
U
W
G
Reuters - 2週前

European shares fall as SAP drags, investors await U.S. data, ECB

UPDATE 2-European shares fall as SAP drags, investors await U.S. data, ECB For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window Spain 12-month inflation rises to 2.6% in August Germany's SAP slips after peer Oracle sales disappoint STOXX 600 down 0.2%, Germany's DAX falls 0.5% Updated at 1552 GMT By Bansari Mayur Kamdar and Shashwat Chauhan Sept 12 (Reuters) - European shares fell on Tuesday, dragged down by German software maker SAP followin
A
G
N
R
S
A
S
E
F
U
W
G
Reuters - 2週前

Cautious start in Europe as healthcare helps offset losses in tech

LIVE MARKETS-Cautious start in Europe as healthcare helps offset losses in tech STOXX 600 hovers unchanged Airbus sags after Pratt & Whitney engine warning FTSE 100 gains after UK employment, wage data Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at markets.research@thomsonreuters.com CAUTIOUS START IN EUROPE AS HEALTHCARE HELPS OFFSET LOSSES IN TECH (0755 GMT) The start has been modest so far in Europe.
A
A
N
S
A
S
E
F
U
W
G
Reuters - 2週前

Epiroc AB, Metso, Sandvik AB,

EUROPE RESEARCH ROUNDUP-Epiroc AB, Metso, Sandvik AB, Sept 12 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Epiroc AB, Metso and Sandvik AB, on Tuesday. HIGHLIGHTS * Atria ATRAV.HE : Inderes raises to accumulate from reduce * Carbios SA ALCRB.PA : Berenberg initiates with buy rating and EUR 51 price target * Epiroc AB EPIRa.ST : Barclays initiates coverage with underweight rating * Metso METSO.HE : Barclays initiates coverage wit
A
B
G
I
I
L
M
N
P
R
R
S
S
S
W
H
A
A
S
S
S
U
Reuters - 2週前

Novartis Issues Voluntary Nationwide Recall Of One Lot Of Sandimmune Oral Solution 100 Mg/Ml Due To Crystallization

BRIEF-Novartis Issues Voluntary Nationwide Recall Of One Lot Of Sandimmune Oral Solution 100 Mg/Ml Due To Crystallization Sept 11 (Reuters) - Novartis AG NOVN.S : NOVARTIS ISSUES VOLUNTARY NATIONWIDE RECALL OF ONE LOT OF SANDIMMUNE® ORAL SOLUTION (CYCLOSPORINE ORAL SOLUTION, USP), 100 MG/ML DUE TO CRYSTALLIZATION NOVARTIS AG - HAS NOT RECEIVED ANY REPORTS OF ADVERSE EVENTS RELATED TO THIS RECALL, TO DATE NOVARTIS AG: RECALL DUE TO CRYSTAL FORMATION OBSERVED IN SOME BOTTLES, WHICH COULD POTENTIA
N

細節

熱門資產

免責聲明: XM Group提供線上交易平台的登入和執行服務，允許個人查看和/或使用網站所提供的內容，但不進行任何更改或擴展其服務和訪問權限，並受以下條款與條例約束：（i）條款與條例；（ii）風險提示；（iii）完全免責聲明。網站內部所提供的所有資訊，僅限於一般資訊用途。請注意，我們所有的線上交易平台內容並不構成，也不被視為進入金融市場交易的邀約或邀請 。金融市場交易會對您的投資帶來重大風險。

所有缐上交易平台所發佈的資料，僅適用於教育/資訊類用途，不包含也不應被視爲適用於金融、投資稅或交易相關諮詢和建議，或是交易價格紀錄，或是任何金融商品或非應邀途徑的金融相關優惠的交易邀約或邀請。

本網站的所有XM和第三方所提供的内容，包括意見、新聞、研究、分析、價格其他資訊和第三方網站鏈接，皆爲‘按原狀’，並作爲一般市場評論所提供，而非投資建議。請理解和接受，所有被歸類為投資研究範圍的相關内容，並非爲了促進投資研究獨立性，而根據法律要求所編寫，而是被視爲符合營銷傳播相關法律與法規所編寫的内容。請確保您已詳讀並完全理解我們的非獨立投資研究提示和風險提示資訊，相關詳情請點擊 這裡查看。

我們運用 cookies 提供您最佳之網頁使用經驗。更改您的cookie 設定跟詳情。

風險提示：您的資金存在風險。槓桿商品並不適合所有客戶。請詳細閱讀我們的風險聲明。